You want me to do all the work for you. It is not hard to read. They literally state that 'R327 has a compelling profile for a sepsis drug candidate'. The results release on the 19/07/2023 stated the specific plasma concentrations and the urine concentrations. I don't know how much clearer you want them to make it.
From the same document released to the ASX. The graph below shows a significant dose dependent concentration of R327 in subjects’ plasma (blood). The results demonstrate a consistent, steady, and proportional linear increase across measured doses of R327. With no observed commensurate spike in drug concentration, (which can lead to harder-to-control side effects) this will help provide the Company with an optimised dosing regime – a compelling profile for a sepsis drug candidate.'
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)